Talk
Oral Communications
Wed, Nov 18, 2026 · 9:55–10:25 AM EST Ballroom - 4th floor, Boston Marriott Copley Place
About this session
Oral communications: OC23 PrevenTRON: Evaluating the effect of trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer's disease at high risk of clinical decline; OC24 Results of a Phase 1 Trial of Intracerebroventricular Injection of Autologous, Wnt-Activated, Adipose-Derived Stem Cells for Alzheimer's Disease; a First-in-Human Study; OC25 A phase 2 randomized, controlled trial of MK-2214, a novel antibody targeting pS413 tau, in early Alzheimer's disease: Study rationale and design.
Speakers
-
Brigham and Women's Hospital, Harvard Medical School
Chair
-
University of California, San Francisco (UCSF)
Chair